Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Relationship of central corneal thickness and corneal biomechanical properties with antiglaucomatous medication use

Poster Details

First Author: E.Baser TURKEY

Co Author(s):    M. Turkoglu   G. Irey   G. Seymenoglu   H. Mayali     

Abstract Details


To investigate whether central corneal thickness (CCT) and corneal biomechanical features change with antiglaucomatous medications use in glaucoma and ocular hypertension (OHT) patients.


Celal Bayar University School of Medicine, Dept. of Ophthalmology, Cornea and Glaucoma Sections.


Data concerning 189 eyes of 101 patients with glaucoma (84 eyes) or OHT (105 eyes) who were using antiglaucomatous medications or were followed without medications were reviewed. All patients had two examinations at least 6 months apart with Reichert Ocular Response Analyzer (ORA) and with ultrasonic pachymeter. Corneal hysteresis (CH), corneal resistance factor (CRF), Goldmann Correlated intraocular pressure (IOPg) and corneal compensated IOP (IOPcc) were recorded. Changes in the corneal biomechanical parameters and its relationship with use of antiglaucomatous drugs were analyzed.


Eyes without any medications had no significant change in CCT; however CH decreased in correspondence with a mild increase in IOPg and IOPcc. Eyes on antiglacomatous medications had significant decrease in CCT (p:0.00), while CH, CRF, IOPcc and IOPg had not changed significantly. While beta blockers (BB) caused no change in CCT and corneal biomechanical properties, prostaglandin analogues and its fixed combinations with BB showed significant CCT decrease (p:0.00). Dorzolamid-BB fixed combination caused significant increase of CCT(p:0.02), while corneal biomechanical parameters did not change. Decrease in CCT was associated with time for prostaglandin analogues.


Antiglaucomatous medications do not have significant effects on corneal biomechanical parameters as measured with ORA. Medications containing prostaglandin analogues cause significant decrease in CCT with time while dorzolamide containg medications can cause an increase of CCT.

Financial Disclosure:


Back to Poster listing